Table 2.
Pre-treatment profiles of the study population based on proportion scores with the cut-off value of 42 pg/mL for the immunoassay regarding SDF-1α.
| Attributes | Number of Cases in Each Subgroup |
Low SDF-1α (<42 pg/dL) |
High SDF-1α (>42 pg/dL) |
p-Values | ||
|---|---|---|---|---|---|---|
| N | % | N | % | |||
| Total number of patients | 84 | 40 | 48% | 44 | 52% | |
| Age | 0.0303 | |||||
| <55 years | 40 | 24 | 60% | 16 | 40% | |
| ≥55 years | 44 | 16 | 36% | 28 | 64% | |
| Menopausal status | 0.0001 | |||||
| Premenopausal | 27 | 21 | 78% | 6 | 22% | |
| Postmenopausal | 57 | 19 | 33% | 38 | 67% | |
| Body mass index (kg/m2) | 0.3237 | |||||
| ≤24.9 | 39 | 22 | 56% | 17 | 44% | |
| 25.0–29.9 | 30 | 12 | 40% | 18 | 60% | |
| 30.0–39.9 | 15 | 6 | 40% | 9 | 60% | |
| Tumour size | 0.4057 | |||||
| T1 < 2 cm | 55 | 28 | 51% | 27 | 49% | |
| T2 ≥ 2–5 cm | 29 | 12 | 41% | 17 | 59% | |
| Nodal status | 0.4489 | |||||
| Negative | 64 | 29 | 45% | 35 | 55% | |
| Positive | 20 | 11 | 55% | 9 | 45% | |
| Stage | 0.6770 | |||||
| IA | 40 | 20 | 50% | 20 | 50% | |
| IIA+IIB | 44 | 20 | 45% | 24 | 55% | |
| ER status | 0.2346 | |||||
| Positive | 74 | 37 | 50% | 37 | 50% | |
| Negative | 10 | 3 | 30% | 7 | 70% | |
| PR status | 0.3677 | |||||
| Positive | 68 | 34 | 50% | 34 | 50% | |
| Negative | 16 | 6 | 37.5% | 10 | 62.5% | |
| HER2 status | 0.6139 | |||||
| Positive | 9 | 5 | 56% | 4 | 44% | |
| Negative | 75 | 35 | 47% | 40 | 53% | |
| Ki67 expression | 0.8023 | |||||
| <20% | 45 | 22 | 49% | 23 | 51% | |
| >20% | 39 | 18 | 46% | 21 | 54% | |
| Histologic grade | 0.8751 | |||||
| G1+G2 | 73 | 35 | 48% | 38 | 52% | |
| G3 | 11 | 5 | 45% | 6 | 55% | |
| Intrinsic subtype of IBrC | 0.5329 | |||||
| Luminal A | 51 | 26 | 51% | 25 | 49% | |
| Luminal B HER (−) | 16 | 7 | 44% | 9 | 56% | |
| Luminal B HER(+) and Non-luminal HER(+) | 9 | 5 | 55% | 4 | 45% | |
| Triple-negative | 8 | 2 | 25% | 6 | 75% | |
| Surgery type | 0.2216 | |||||
| BCS | 69 | 35 | 51% | 34 | 49% | |
| Mastectomy | 15 | 5 | 33% | 10 | 67% | |
| Radiotherapy | 0.8451 | |||||
| Yes | 70 | 33 | 47% | 37 | 53% | |
| No | 14 | 7 | 50% | 7 | 50% | |
| Chemotherapy | 0.6307 | |||||
| Yes | 46 | 23 | 50% | 23 | 50% | |
| No | 38 | 17 | 45% | 21 | 55% | |
| Immunotherapy | 0.5982 | |||||
| Yes | 7 | 4 | 57% | 3 | 43% | |
| No | 77 | 36 | 47% | 41 | 53% | |
| Hormone therapy | 0.2346 | |||||
| Yes | 74 | 37 | 50% | 37 | 50% | |
| No | 10 | 3 | 30% | 7 | 70% | |
SDF-1α—stromal cell-derived factor 1α; ER—oestrogen receptor; PR—progesterone receptor; HER2—human epidermal growth factor receptor 2; Ki67—proliferation marker; G1—well-differentiated (grade 1); G2—moderately differentiated (grade 2); G3—poorly differentiated; BCS—breast-conserving surgery; significant differences are denoted by bold.